Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013

Abstract Background Although cisplatin and 5-chloro-2,4-dihydropyrimidine (dihydropyrimidine dehydrogenase inhibitor contained in S-1) are excreted into the urine, it remains unknown how creatinine clearance (CrCl) affects the safety and efficacy of cisplatin plus S-1 and docetaxel plus cisplatin pl...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2022-01, Vol.52 (1), p.14-23
Main Authors: Hironaka, Shuichi, Sadachi, Ryo, Machida, Nozomu, Iwasa, Satoru, Yamada, Yasuhide, Sasako, Mitsuru, Yoshikawa, Takaki, Boku, Narikazu, Terashima, Masanori
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cisplatin - adverse effects
Docetaxel - adverse effects
Humans
Kidney - physiology
Stomach Neoplasms - drug therapy
Taxoids - adverse effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Although cisplatin and 5-chloro-2,4-dihydropyrimidine (dihydropyrimidine dehydrogenase inhibitor contained in S-1) are excreted into the urine, it remains unknown how creatinine clearance (CrCl) affects the safety and efficacy of cisplatin plus S-1 and docetaxel plus cisplatin plus S-1 in patients with advanced gastric cancer. Methods Among the 741 participants in JCOG1013 comparing cisplatin plus S-1 with docetaxel plus cisplatin plus S-1, 723 with serum creatinine levels ≤1.2 mg/dL were categorized into A1 (CrCl ≥ 80 mL/min), A2 (60 ≤ CrCl
ISSN:1465-3621
1465-3621
DOI:10.1093/jjco/hyab160